Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EVT 302

Small molecule · developed by Evotec Neurosciences GmbH

Phase 2 Most advanced trial (none active)
EVO Developer
2 Registered trials

What is EVT 302?

EVT 302 is a drug studied in smoking cessation, given double-blind alongside open-label nicotine replacement.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Psychiatry
Developer
Evotec Neurosciences GmbH (EVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00738595 Phase 2 Smoking Cessation Completed EVO
NCT00622752 Phase 2 Smoking Cessation Completed EVO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Smoking Cessation

More from Evotec Neurosciences GmbH

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the EVO page.

Follow EVO, the company behind EVT 302

See EVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.